Our discovery that increased BACH2 expression correlates with increased risk of BCC (+bSMR), alongside identification of a BCC-associated methylation site in the promoter of BACH2 which increases gene expression, suggests a molecular mechanism whereby elevated levels of BACH2 promote tumour immunosuppression by attenuating effector T cells. The gene discussed is BACH2; the disease is neoplasm.